Lung Cancer

My first oncologist got me started with positivity in my cancer journey, which I was thankfully able to internalize.

Alecensa cut the risk of death by 22% versus Xalkori, with median overall survival reaching 81.1 months versus 54.2 months in advanced ALK-positive lung cancer.

The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.

Experts discuss how better hospice and home care reimbursement can help patients receive compassionate end-of-life care at home.

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

LiveLung, a nonprofit organization, invites the CSRA’s lung cancer community to its educational meeting.

Brittney Nichols discussed the emotional and physical side effects of lung cancer treatment, as well as feelings of isolation in newly diagnosed patients.

Brittney Nichols highlights the need for early detection and stresses that lung cancer is not only caused by smoking; anyone can develop the disease.

Although a cancer diagnosis can feel overwhelming and isolating, patients should know that they are never alone, Brittney Nichols emphasized.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.

LiveLung, a nonprofit organization dedicated to supporting lung cancer patients, invites the Charlotte cancer community to its monthly educational meeting.

Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens.

As we approach Lung Cancer Awareness Month this November, it’s important to reflect on the latest developments and insights in lung cancer research.

Dr. Fred Hirsch highlighted how knowledge of the molecular characteristics of non-small cell lung cancer enhances understanding of the disease.

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.

Kelly Dyckman works to help women reclaim their confidence in intimacy following a cancer journey, as she explained in an interview with CURE.

The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.